HbA1c Testing Devices Market Report Scope & Overview:

The HbA1c Testing Devices Market was valued at USD 2.33 Billion in 2025 and is expected to reach USD 5.22 Billion by 2035, growing at a CAGR of 8.42% from 2026 to 2035.

The HbA1c testing devices are the medical instruments utilized for measuring the level of the glycated hemoglobin in the individual's blood, which is considered a crucial biomarker in the diagnosis and treatment of diabetes, including both lab devices and point-of-care devices, which offer relatively quick and accurate results. Contrary to periodic measurement of the glucose, the HbA1c testing gives cumulative information about the presence of high glycemic levels in the organism, making this procedure crucial both for diagnosis and disease control. The development and growth of the market for the HbA1c testing devices are driven by structural factors such as the increased importance of glycemic control, the trend of decentralizing diagnostic processes close to the patient, and chronic disease monitoring at the level of primary care.

The Abbott Laboratories introduced a new portable HbA1c testing kit in August 2025 aimed at remote locations where access to health care services is a challenge for people suffering from diabetes and is seen as a step in line with the overall company strategy of expanding the provision of diabetes care globally.

Market Size and Forecast

• Market Size in 2026E: USD 2.52 Billion
• Market Size by 2035: USD 5.22 Billion
• CAGR: 8.42% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

HbA1c Testing Devices Market Trends

• Companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency across a moderately fragmented competitive landscape.
• Development of portable HbA1c testing devices for home use continues expanding accessibility beyond traditional clinical settings.
• Integration of AI-driven analytics for personalized diabetes management continues enhancing clinical decision support capability.
• Expansion of telehealth services for remote HbA1c monitoring continues reshaping how patients access ongoing glycemic control testing.
• Rapid microfluidic assay technology continues enabling accurate test results in as little as seven minutes, meeting clinical demand for rapid diagnostics.

The United States HbA1c Testing Devices Market Outlook

The United States HbA1c Testing Devices Market was valued at USD 0.712 Billion in 2025 and is expected to reach USD 1.610 Billion by 2035, growing at a CAGR of 8.50% from 2026 to 2035.

US is still the largest market for HbA1c testing instruments driven by widespread presence of diabetes, extensive reimbursement system in health care, and adoption of clinical laboratories and point-of-care testing. Demand for fast and reliable point-of-care testing increased during the year, which made companies invest more into the creation of portable testing analyzers because there was an increasing demand for instant analysis results which could allow timely adjustment of treatment.

Tosoh Bioscience received approval from the United States Food and Drug Administration in October 2025 for its new HbA1c testing device, the GR01, which can check long-term blood sugar for people with diabetes, help diagnose diabetes, and identify individuals who may be at risk of developing the condition.

HbA1c Testing Devices Market Segment Analysis

• By Device Type, the point-of-care devices segment held approximately 76.53% share in the HbA1c testing devices market in 2025, while the same segment is also the fastest growing, with a CAGR of approximately 6.92%.
• By Technology, the HPLC segment held approximately 61.12% share in the HbA1c testing devices market in 2025, while the immunoassay segment is the fastest growing, with a CAGR of approximately 7.00%.
• By End-User, the hospitals segment held approximately 41.38% share in the HbA1c testing devices market in 2025, while the diagnostic and reference laboratories segment is the fastest growing.
• By Patient Age Group, the adults segment held the largest share in the HbA1c testing devices market in 2025, while the geriatric segment is the fastest growing.

By Device Type, point-of-care devices segment dominates the HbA1c testing devices market, and also grows fastest

The point-of-care devices segment held approximately 76.53% of total market revenue in 2025, and is also projected to grow at the fastest CAGR of approximately 6.92% during the forecast period, reflecting growing preference for decentralized, rapid testing aligned with patient-centric care models. That dual leadership and continued growth trajectory reflects how comprehensively point-of-care testing continues capturing clinical preference relative to the broader device type segmentation, with portability, ease of use, and faster turnaround times, often delivering results within minutes, continuing to boost clinical workflows and enable timely therapeutic interventions across pharmacy, clinical, and home-care settings, while benchtop laboratory analyzers continue serving as the backbone of high-throughput laboratories processing thousands of specimens daily.

By Technology, HPLC segment dominates the HbA1c testing devices market, immunoassay grows fastest

The HPLC segment held approximately 61.12% of total market revenue in 2025, remaining the reference-standard technology for HbA1c measurement given its established analytical precision and widespread adoption across high-throughput laboratory settings. That established analytical credibility continues to keep HPLC firmly at the top of the broader technology segmentation across nearly every major diagnostic laboratory worldwide.

The immunoassay segment is projected to grow at the fastest CAGR of approximately 7.00% during the forecast period, with immunoassay-based technologies underpinning many point-of-care devices and contributing to their enhanced specificity and robustness in non-laboratory settings. Rising adoption of immunoassay-based point-of-care platforms continues pushing this technology category's growth rate ahead of the broader technology segmentation.

By End-User, Hospitals Segment dominates the HbA1c testing devices market, while diagnostic and reference laboratories grows fastest

The hospitals segment held approximately 41.38% of total market revenue in 2025, anchored by comprehensive diagnostic infrastructure and the clinical oversight that complex diabetes management protocols continue requiring. That established clinical infrastructure continues to keep hospitals firmly at the top of the broader end-user segmentation across nearly every major regional healthcare market worldwide.

The diagnostic and reference laboratories segment is projected to grow at the fastest CAGR during the forecast period, as centralized reference laboratories increasingly process high-throughput HbA1c testing for multiple healthcare provider networks simultaneously. Rising outsourcing of specialized diagnostic testing continues pushing this end-user category's growth rate ahead of the broader end-user segmentation.

By Patient Age Group, adults segment dominates the HbA1c testing devices market, while geriatric grows fastest

The adults segment held the largest share of the patient age group segmentation in 2025, reflecting the substantial adult Type 2 diabetes patient population that continues representing the primary driver of HbA1c testing demand worldwide. That substantial, sustained adult patient population continues to keep this age group firmly at the top of the broader patient age group segmentation.

The geriatric segment is projected to grow at the fastest CAGR during the forecast period, as rising diabetes prevalence among aging populations continues expanding demand for regular glycemic monitoring among elderly patients managing multiple chronic conditions. Rising geriatric diabetes prevalence continues pushing this patient age group category's growth rate ahead of the broader patient age group segmentation.

Regional Analysis

North America HbA1c Testing Devices Market Insights

North America held the largest share of the global HbA1c Testing Devices Market in 2025, supported by high diabetes prevalence and comprehensive healthcare reimbursement infrastructure across the region. Growing demand for rapid, on-site diagnostic testing continued reinforcing this leadership position throughout the year.

The United States accounted for roughly 84.80% of regional revenue, reflecting its concentration of leading diagnostics manufacturers and comprehensive clinical and point-of-care testing infrastructure. Canada contributed a smaller but steadily growing share of regional revenue, supported by its own expanding diabetes screening programs, keeping North America firmly ahead of every other region in this market.

Europe HbA1c Testing Devices Market Insights

Europe had a large market share in the HbA1c Testing Devices Market of the world in 2025 owing to the availability of national health insurance coverage in addition to a well-developed diagnostics manufacturing base in Europe. In this regard, Germany had about 27.10% market share owing to presence of diagnostics manufacturers in the country.

France, the United Kingdom, and Italy followed a broadly similar trajectory, as continued investment in decentralized diagnostics extended HbA1c testing devices demand across the continent's largest healthcare markets. Continued regulatory support for point-of-care diagnostic innovation is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific HbA1c Testing Devices Market Insights

Asia Pacific was the fastest-growing region in the global HbA1c Testing Devices Market, supported by rapidly rising diabetes prevalence, expanding healthcare infrastructure investment, and growing government-backed diabetes screening programs across the region's largest and most populous economies. Rising healthcare access continued driving regional demand at a pace considerably faster than more mature Western markets.

China accounted for roughly 36.30% of regional revenue, supported by expanding domestic healthcare infrastructure and growing diagnostic testing access. India and Japan contributed significant additional regional demand through their own expanding diabetes screening infrastructure, reinforcing Asia Pacific's position as the clear growth leader in this market.

MEA & Latin America HbA1c Testing Devices Market Insights

The Middle East and Africa region recorded steady growth in HbA1c testing devices adoption in 2025, driven by expanding healthcare infrastructure investment and growing government support for diabetes screening programs across the Gulf states in particular. The UAE accounted for roughly 26.20% of regional revenue, supported by national healthcare modernization strategies and rising demand for advanced diagnostic technology.

Latin America expanded at a comparable pace, led by Brazil at roughly 37.00% of regional revenue, where growing healthcare infrastructure investment continued to support category growth. Mexico and Argentina followed a similar trajectory as regional diabetes screening access expanded further through the remainder of the forecast period.

Market Dynamics

Growth Drivers: Rising Diabetes Prevalence and Diagnostics Decentralization

Rising diabetes prevalence, particularly Type 2 Diabetes Mellitus, continues driving sustained growth of the HbA1c testing devices market, with the International Diabetes Federation estimating hundreds of millions of adults globally living with diabetes. The decentralization of diagnostics toward near-patient settings and the integration of chronic disease monitoring into primary care pathways continue reinforcing structural demand growth across nearly every major regional healthcare market worldwide.

Technological advancement in clinical diagnostics and increasing focus on research for development of novel diagnostics continue reinforcing sustained market expansion. Economically superior point-of-care devices represent a prime opportunity amid increasing healthcare decentralization, continuing to drive development of portable diagnostic analyzers across clinical, pharmacy, and home-care settings.

Restraints: Reimbursement Variability and Point-of-Care Accuracy Standardization

Variability in reimbursement frameworks for point-of-care HbA1c testing across different healthcare systems continues creating genuine market access uncertainty for device manufacturers and healthcare providers. That reimbursement variability continues requiring sustained advocacy and health economic evidence generation to support broader point-of-care testing adoption.

Maintaining consistent analytical accuracy across decentralized point-of-care testing environments, relative to the established precision of centralized laboratory HPLC systems, continues requiring rigorous quality assurance protocols. That standardization requirement continues concentrating the most clinically trusted point-of-care technology among established, well-validated device manufacturers.

Opportunities: Home-Use Device Development and AI-Driven Analytics Integration

Continued development of portable HbA1c testing devices for home use presents substantial opportunity for manufacturers positioned to serve patients seeking convenient, self-managed glycemic monitoring outside clinical settings. Manufacturers capable of delivering accurate, user-friendly home testing devices stand to capture a growing share of demand as this technology continues maturing.

Integration of AI-driven analytics for personalized diabetes management presents a further significant growth avenue, as these devices increasingly provide feedback that allows providers to adjust treatment in real time for improved patient outcomes. Manufacturers capable of delivering genuinely intelligent, connected testing platforms stand to capture meaningful new revenue streams through 2035.

Recent Developments:

• 2025: LumiraDx continued advancing its rapid microfluidic assay technology, providing accurate HbA1c test results in as little as seven minutes to meet clinical demand for easy, reliable diabetes screening methods.
• 2025: Roche continued expanding its HbA1c testing device portfolio, strengthening its position serving hospitals and diagnostic laboratories requiring high-throughput, precise glycemic monitoring technology.
• 2025: Bio-Rad Laboratories continued advancing its diagnostic testing platform, targeting clinical laboratories seeking reliable, high-volume HbA1c analysis capability.

HbA1c Testing Devices Market key players are:

• Abbott Laboratories
• ARKRAY, Inc.
• Bio-Rad Laboratories, Inc.
• Polymer Technology Systems, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Trinity Biotech plc
• LumiraDx Limited
• Siemens Healthineers AG
• Tosoh Corporation
• EKF Diagnostics Holdings plc
• Diazyme Laboratories, Inc.
• Sekisui Diagnostics, LLC
• Erba Mannheim
• Randox Laboratories Ltd.
• HemoCue AB
• i-SENS, Inc.
• Menarini Diagnostics S.r.l.
• Quidel Corporation
• Werfen Group

HbA1c Testing Devices Market Report Scope :